Wegovy HD (Semaglutide 7.2 mg): Complete Guide to the New Higher-Dose Weight Loss Injection
Current Wegovy HD label, STEP UP results and estimand differences, adverse effects and product-specific treatment limits.
Current Label and Eligibility
Current Wegovy labeling includes a 7.2 mg/0.75 mL single-dose pen called Wegovy HD. For adult weight reduction, escalation to a maximum 7.2 mg weekly may be considered after tolerating 2.4 mg for at least four weeks when additional reduction is clinically indicated. This is not a starting dose or a requirement for every plateau.
The 7.2-mg adult weight instruction is not the pediatric, cardiovascular or MASH maintenance regimen. Ozempic, oral Wegovy and other semaglutide products have different indications and dosing; do not combine products or build intermediate doses from pen arithmetic.
STEP UP: Same-Trial Comparisons
STEP UP randomized 1,407 adults with obesity (BMI at least 30) without diabetes to weekly 7.2 mg, 2.4 mg or placebo plus lifestyle intervention for 72 weeks. Its treatment-policy analysis found mean weight changes of −18.7%,−15.6% and −3.9%, respectively: a 3.1-percentage-point 7.2-versus 2.4 difference. The frequently cited 20.7% figure uses a different trial-product estimand; it should not be compared with an unrelated 15% trial as a 5–6-point advantage.
More participants reached high weight-loss thresholds with 7.2 mg. These are meaningful positive group outcomes, not an individual forecast or proof of diabetes reversal, surgery equivalence or greater cardiovascular benefit. A separate diabetes trial has a different population. The published STEP UP arms were 7.2 mg, 2.4 mg and placebo, not a 4 mg maintenance option.
Adverse Effects and Treatment Review
GI adverse events occurred in 70.8%, 61.2% and 42.8% in the 7.2 mg, 2.4 mg and placebo groups; dysaesthesia occurred in 22.9%, 6.0% and 0.5%. Altered skin sensation should not automatically be called harmless or guaranteed to resolve. Discuss significant symptoms and tolerability with the prescriber.
Pancreatitis, gallbladder disease, volume-depletion kidney injury and severe GI warnings remain relevant. Personal/family MTC or MEN2 is a contraindication; rodent thyroid findings have uncertain human relevance. A dose increase is a clinical decision, not a home workaround for inadequate response. Severe persistent abdominal pain or inability to maintain fluids needs prompt assessment.
Access, Comparisons and Next Steps
Wegovy HD is a currently labeled option; an April 2026 launch forecast is no longer a current availability check. Confirm actual pharmacy stock, prescribed presentation, current itemized price, coverage and assistance eligibility. Historical standard-Wegovy prices and anticipated insurance terms do not establish today's HD cost or coverage. For the provider side of weight management, SurpassMD describes its program and assessment process.
Cross-trial figures do not establish superiority over tirzepatide, CagriSema, retatrutide or surgery. Their products, populations, endpoints and regulatory states differ. Do not present an anticipated oral tirzepatide or a 4 mg injection as a currently approved step. Choose care using the actual indication, response, risks, access and preferences.
Frequently Asked Questions
It is the 7.2 mg/0.75 mL single-dose Wegovy semaglutide pen. The current label permits selected adult weight-reduction escalation after 2.4 mg tolerance; it is not a starting dose.
STEP UP treatment-policy results were 18.7% mean reduction at 7.2 mg versus 15.6% at 2.4 mg over 72 weeks. 20.7% uses a different estimand. Trial averages are not personal forecasts.
The adult weight-reduction label permits escalation after at least four weeks tolerating 2.4 mg when additional reduction is clinically indicated. Other indications and pediatric dosing differ.
It is currently labeled. Confirm actual local stock and the prescribed presentation; an April 2026 launch forecast is not a current availability check.
Check a current itemized quote, plan coverage and assistance eligibility. Historical standard-dose prices or anticipated HD terms do not establish today’s out-of-pocket cost.
GI effects and dysaesthesia were more frequent at 7.2 mg in STEP UP. Serious product warnings still apply; altered sensation is not automatically harmless or guaranteed to resolve.
A clinician may consider the labeled step after 2.4 mg tolerance and assessment of need. Do not combine pens, invent an intermediate dose or transfer instructions from another formulation.
No direct comparison of these specific HD and tirzepatide doses is established here. Different trial estimands and populations cannot supply a universal winner.
A 72-week randomized trial in 1,407 adults with obesity without diabetes compared 7.2 mg, 2.4 mg and placebo. It did not establish a 4 mg injection maintenance option.
Both contain semaglutide, but the products, presentations, indications and doses differ. Neither a nominal milligram comparison nor a shared ingredient makes them interchangeable.